Magazine Article | March 22, 2018

Vertical Mergers Of Rx Supply Chain Spark Antitrust Concerns

By John McManus, The McManus Group

The recent announcement of two vertical mergers ­— the $52 billion acquisition of Express Scripts, the largest pharmacy benefit manager (PBM) in the country, by Cigna, and the $69 billion purchase of Aetna by CVS Health — raise significant antitrust concerns over how these megacompanies will impact patient access and pharmaceutical pricing.

The Justice Department is now reviewing the Aetna-CVS deal and is expected to do the same for the proposed Express Scripts and Cigna merger.

THIS CONTENT IS EXCLUSIVELY FOR LIFE SCIENCE LEADER PAID SUBSCRIBERS.
To continue reading this story and receive uninterrupted access to LSL Online and its monthly magazine subscribe to Life Science Leader today!
Already a subscriber? Log in now.